Cargando…

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer

According to clinical and pathological factors the prognosis of a patient with non-muscle invasive bladder tumors can be assessed. The prognosis is determined by the likelihood of recurrence(30-70%) and/or progression to muscle invasive bladder cancer(1-15%).Trans urethral resection of bladder tumor...

Descripción completa

Detalles Bibliográficos
Autor principal:	van der Meijden, A.P.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2006
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917213/ https://www.ncbi.nlm.nih.gov/pubmed/17619738 http://dx.doi.org/10.1100/tsw.2006.403

Ejemplares similares

New therapies in nonmuscle invasive bladder cancer treatment
por: Rayn, Kareem N., et al.
Publicado: (2018)

Diagnostics techniques in nonmuscle invasive bladder cancer
por: Soubra, Ayman, et al.
Publicado: (2015)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Active surveillance for nonmuscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2016)

Advances in nonmuscle invasive bladder cancer
por: Konety, Badrinath R.
Publicado: (2015)

Nonmuscle invasive bladder cancer: a primer on immunotherapy
por: Maruf, Mahir, et al.
Publicado: (2016)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study
por: Jian, Xiaoming, et al.
Publicado: (2019)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer
por: Ruan, Qiang, et al.
Publicado: (2021)

A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
por: Joshua, Julie Mariam, et al.
Publicado: (2019)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
por: Correa, Andres F., et al.
Publicado: (2015)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer
por: Lilge, Lothar, et al.
Publicado: (2020)

The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer
por: Cahill, Ellen M., et al.
Publicado: (2022)

Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer
por: Sahu, Divya, et al.
Publicado: (2017)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer (Erratum)
por: Lilge, Lothar, et al.
Publicado: (2020)

Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy
por: Rao, Manoj V., et al.
Publicado: (2013)

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
por: Wettstein, Marian S., et al.
Publicado: (2015)

Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification
por: Wang, Hui, et al.
Publicado: (2018)

New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer
por: Ather, M Hammad, et al.
Publicado: (2015)

Efficacy of pirarubicin for nonmuscle invasive bladder cancer: A protocol of systematic review and meta-analysis
por: Chen, Da-Yin, et al.
Publicado: (2020)

Assessment of Pain Management, Acceptance of Illness, and Adjustment to Life with Cancer in Patients with Nonmuscle Invasive Bladder Cancer
por: Krajewski, Wojciech, et al.
Publicado: (2018)

Impact of maintenance therapy using a half dose of the bacillus Calmette–Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study
por: Koguchi, Dai, et al.
Publicado: (2020)

Erectile dysfunction in nonmuscle-invasive bladder cancer patients before and after transurethral resection (TUR) of bladder tumor in China
por: Guo, Peng, et al.
Publicado: (2021)

Adjuvant Treatment of Intermediate Risk Non-muscle Invasive Bladder Cancer
por: DRĂGOESCU, O., et al.
Publicado: (2014)

Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder
por: Lim, So Dug, et al.
Publicado: (2015)

MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer
por: Mitash, Nilay, et al.
Publicado: (2017)

Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients
por: Lu, Mengxin, et al.
Publicado: (2019)

A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer
por: Bellat, Vanessa, et al.
Publicado: (2022)

Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study
por: Catto, James W. F., et al.
Publicado: (2021)

Psychometric Evaluation of a Patient-Reported Symptom Index for Nonmuscle Invasive Bladder Cancer: Field Testing Protocol
por: Rutherford, Claudia, et al.
Publicado: (2017)

Clinical Implications and Prognostic Values of Prostate Cancer Susceptibility Candidate Methylation in Primary Nonmuscle Invasive Bladder Cancer
por: Kim, Young-Won, et al.
Publicado: (2015)

The value of extensive transurethral resection in the diagnosis and treatment of nonmuscle invasive bladder cancer with respect to recurrence at the first follow-up cystoscopy
por: Qie, Yunkai, et al.
Publicado: (2016)

Dose, duration and strain of bacillus Calmette–Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials
por: Quan, Yongjun, et al.
Publicado: (2017)

Nonmuscle Tissues Contribution to Cancer Cachexia
por: Argilés, Josep M., et al.
Publicado: (2015)

Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer
por: Tsuji, Shingo, et al.
Publicado: (2016)

Can tumor recurrence be reduced with plasma-kinetic vaporization of the area around the tumor in nonmuscle invasive bladder cancer?
por: Yılmaz, Yüksel, et al.
Publicado: (2018)

Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis
por: Zhang, Dong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v16me8jmcb2s7g2i91ie7d2v6q